From the *WA PET Service, Nuclear Medicine Department, Sir Charles Gairdner Hospital, Nedlands; and †Nuclear Medicine Department, Royal Perth Hospital, Perth, Western Australia, Australia.
Clin Nucl Med. 2015 May;40(5):e285-6. doi: 10.1097/RLU.0000000000000681.
We present the case of a 60-year-old male patient with T3b-N1, Gleason score 8, adenocarcinoma prostate with biochemical relapse (prostate-specific antigen, 5.2 μg/L) 1 year after radical treatment with 50.4-Gy 3-dimensional conformal radiotherapy and androgen deprivation therapy. Conventional imaging including contrast-enhanced abdominal CT and whole-body bone scintigraphy did not reveal any local recurrence or distant metastases. F-flourocholine PET/CT demonstrated a solitary, intensely avid (SUVmax, 9.2) osteolytic metastasis in the manubrium. Histopathology confirmed metastatic prostate adenocarcinoma.
我们报告一例 60 岁男性患者,T3b-N1,Gleason 评分 8,前列腺腺癌,根治性治疗后 1 年发生生化复发(前列腺特异抗原,5.2μg/L),治疗方案为 50.4Gy 三维适形放疗联合雄激素剥夺治疗。常规影像学检查,包括增强腹部 CT 和全身骨扫描,未发现局部复发或远处转移。氟-18 胆碱 PET/CT 显示胸骨柄单发、高度摄取(SUVmax,9.2)溶骨性转移病灶。组织病理学证实为转移性前列腺腺癌。